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Introduction
9-Phenanthrol, known as a phenanthrene derivative, is first described as a specific inhibitor of the transient receptor potential melastatin 4 (TRPM4) channel, which refers to a Ca 2+ -activated non-selective cation channel that is widely expressed in mammalian tissues . It shows no effect on the closely related TRPM5 channel or on other members of the transient receptor potential channel family (Gonzales et al., 2010; Guinamard et al., 2014) ; its IC 50 for TRPM4 is approximately 20 μM. Therefore, 9-phenanthrol has long been used as a pharmacological tool to identify the physiological and pathophysiological roles of the TRPM4 channel in various biological preparations including neurons, hearts and detrusor smooth muscles (Mrejeru et al., 2011; Hof et al., 2013; Simard et al., 2013; Smith et al., 2013; Hof et al., 2016) . Recent studies using 9-phenanthrol in the cardiovascular system have unmasked the important roles of TRPM4 in arrhythmogenesis (Simard et al., 2012) and in the modulation of the heart rate and action potential duration (APD) of cardiomyocytes Hof et al., 2016) . However, the effect of 9-phenanthrol on the cardiac sodium channel has not yet been investigated. Although previous studies in cardiac preparations suggest that 9-phenanthrol (10-100 μM) does not influence the maximum upstroke velocity (Vmax) of the action potential (AP) or the action potential amplitude (APA) Simard et al., 2013; Hof et al., 2016) , the two peak sodium current (I NaP )-dependent parameters, a direct effect of 9-phenanthrol on cardiac sodium channel cannot be excluded, especially on the late sodium current (I NaL ), which contributes importantly to cardiac repolarization. Cardiac I NaL has recently been demonstrated as a promising antiarrhythmic target, inhibition of which can ameliorate abnormal Na + influx into cardiomyocytes, restore intracellular Ca 2+ homeostasis, enhance repolarization reserve, decrease transmural dispersion of repolarization and consequently terminate arrhythmias (Belardinelli et al., 2015; Rajamani et al., 2016) . Our previous studies (Hou et al., 2016; Li et al., 2017) have demonstrated that I NaL in Purkinje cells (PCs) is usually larger than that in ventricular myocytes (VMs), consistent with a longer APD in PCs. Importantly, I NaL inhibitors, such as tetrodotoxin (TTX) and ranolazine, shorten the APD of PCs to a larger extent than that of VMs (Aomine, 1989) . More recently, Guinamard et al. (Hof et al., 2016) showed that the TRPM4 inhibitor 9-phenanthrol shortened the APD in rabbit Purkinje fibres but not in ventricles. However, it is unclear whether the selective effect of 9-phenanthrol on cardiac Purkinje fibres involves I NaL , the important repolarization current in Purkinje fibres. Therefore, in the present study, we examined the effects of 9-phenanthrol on the cardiac sodium current by directly recording I NaP and I NaL in isolated VMs, PCs and in HEK293 cells transfected with long QT syndrome type 3 (LQT3) mutations. In addition, we also studied its effect on Anemonia toxin II (ATX-II)-induced arrhythmias both in isolated cells and arterially perfused wedge preparations.
Methods
The experiments involving animals were approved by the ethics committee of Xinhua Hospital and conformed to the Guide for the Care and Use of Laboratory Animals of Shanghai, China. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010) . A total of 50 New Zealand rabbits (2-3 kg, 12-16 weeks old) of either sex were chosen for study in our experiments, as the electrophysiological properties of rabbit tissues share many similarities with those of humans and have long been used for testing anti-and pro-arrhythmic properties of compounds. Animals were bought from Slaccas Experimental Animal Company (Shanghai, China). The rabbits were housed in individually ventilated cages (1 m 2 , with wood chip bedding)
with free access to water. Rabbits were fed food pellets twice a day and kept in a 12 h light-dark cycle at 25°C. All efforts were made to reduce the number of animals required to obtain reliable results and minimize the suffering of the animals based on the rule of the replacement, refinement and reduction (the 3Rs).
Isolation of cardiac myocytes
Single VMs and cardiac PCs were isolated using an enzymatic dissociation technique (Scamps and Carmeliet, 1989 Arterially perfused rabbit left ventricular wedge preparation
As described previously (Wang et al., 2008) , New Zealand rabbits (2-3 kg, 12-16 weeks old) of either sex were administered heparin (1000 U·kg À1 ) and anaesthetized with sodium pentobarbital (50 mg·kg À1 ) via the marginal ear vein; the heart was rapidly excised and placed in a cardioplegic solution (4°C), and then cannulated via the left circumflex branch of the coronary artery and perfused with cardioplegic solution. This procedure was completed within 4 min. Un-perfused areas of the left ventricle, which were identified by their reddish appearance, were removed. The preparation was then placed in a tissue bath containing (in mM) NaCl 129, KCl 4, NaH 2 PO 4 0.9, NaHCO 3 20, CaCl 2 1.8, MgSO 4 0.5, glucose 5.5, pH 7.35 buffered with 95% O 2 /5% CO 2 . The same solution was used to perfuse the preparation, and the perfusion temperature and pressure were maintained at 35.7 ± 0.1°C and 35-45 mmHg respectively. The wedge preparation was paced with bipolar silver electrodes, at basic cycle lengths (BCLs) of 1000 and 2000 ms, placed on the endocardium. Before recording, the preparation was allowed to equilibrate for 1 h in the tissue bath. Preparations with significant ST segment elevation or depression, or with an obvious temperature gradient along the length of the preparation were excluded. Floating glass microelectrodes were used to record APs from the endocardium. Extracellular silver/silver chloride electrodes placed near the epicardial and endocardial surfaces were used to record transmural ECG. The QT interval was defined as the time from the onset of the QRS to the end of the T wave. The Tp-e interval was defined as the time from the peak to the end of the T wave. QT interval, QRS duration and Tp-e interval were measured throughout the experiment.
Na v 1.5 mutagenesis
The wild-type (WT) SCN5A vector (pcDNA3.1) was a gift from Professor Kejiang Cao (Nanjing Medical University, China). The S1904L and ΔKPQ mutants of SCN5A were generated using the site-directed mutagenesis technique and confirmed by complete sequencing. S1904L were generated using the forward primer: 5 0 -CAAGCACGAAGAGGTGTTGGCCATGGTTATCCAG-3 0 and the reverse primer: 5 0 -CTGGATAACCATGGCCAACACCTC TTCGTGCTTG-3 0 . ΔKPQ were generated using the forward primer: 5 0 -GCCATGAAGAAGCTGGGCTCCAAGAAGCCCA TCCCACGGCCCCTGAAC-3 0 and the reverse primer:
Cell culture HEK293 cells were seeded onto 35 mm culture dishes in DMEM supplemented with 10% FCS and 0.1% penicillin/streptomycin at 37°C in 5% CO 2 . Vector encoding WT, S1904L or ΔKPQ mutant of SCN5A and vector encoding green fluorescent protein were co-transfected into HEK293 cells using Lipofectamine 2000 (Invitrogen, USA). Cells were seeded at 20-30% confluence onto cover glasses 36 h after transfection. After 3-4 h of adherence, the cover glasses were transferred to a patch chamber. Cells that displayed green fluorescence under the fluorescence microscope were chosen for electrophysiological studies. EADs were defined as depolarizations during repolarization that were >2 mV in amplitude. After steady EADs were elicited, 9-phenanthrol or flufenamic acid (FA) was added to the bath solution. Ionic currents were recorded at room temperature (20-23°C), and series resistance was electrically compensated to 70-80%. To record the I NaL in both cardiomyocytes and HEK293 cells, pipette resistance was adjusted to 1-2 MΩ. The external solution contained (in mM): 135 NaCl, 5.4 CsCl, 1.0 MgCl 2 , 10 glucose, 0.33 NaH 2 PO 4 , and 10 HEPES, 1.8 CaCl 2 , 0.03 nifedipine, pH 7.4 (NaOH). The internal solution contained (in mM): 30 CsCl, 110 Cs-aspartate, 0.2 Na 3 -GTP, 10 HEPES, 0.5 EGTA, 5 MgATP, 5 Na 2 -phosphocreatine, pH 7.2 (CsOH). The I NaL was recorded by 300 ms voltageclamp pulses from À120 to À20 mV at 0.2 Hz and measured at 200 ms by subtracting the value in the presence of 10 μM TTX. As the endogenous I NaL in VMs was relatively small, 10 nM ATX-II was used to amplify it. To study the dose-response relationship for the effect of 9-phenanthrol on I NaL in VMs, five concentrations (1, 10, 30, 50 and 100 μM) of 9-phenanthrol were used to calculate an IC 50 . The I NaL was recorded under control conditions and 4 min following the addition of 9-phenanthrol. TTX (10 μM) was added to quantify the I NaL . Most of the cells were unable to tolerate a long time recording and leak current increased in a time-dependent manner. Thus, each cell was only exposed to two or three concentrations of 9-phenanthrol. At 1 μM, the inhibitory effect of 9-phenanthrol on I NaL was comparatively low but increased at higher concentrations and with greater variability. Consequently, more cells were tested at higher concentrations of 9-phenanthrol.
Patch clamp study
To record the I NaP , the pipette solution was the same as that for I NaL . The bath solution contained (in mM): 10 NaCl, 130 CsCl, 1.0 CaCl 2 , 10 glucose, 1.0 MgCl 2 , 5 HEPES and 0.3 CdCl 2 , pH 7.4 (CsOH). The I NaP was elicited by a 40 ms depolarizing voltage step from À70 to +45 mV at a holding potential of À120 mV.
To record the L-type calcium current (I CaL ), cells were perfused with a modified Tyrode solution in which KCl was replaced with the equivalent CsCl, and TTX (10 μM) were added to block I NaL . The pipettes (resistance 2 to 4 MΩ) were filled with solution containing (in mM): 20 CsCl, 100 Cs-aspartate, 1 MgCl 2 , 10 EGTA, 20 TEACl, 10 HEPES, and 5 MgATP, pH 7.2 adjusted with CsOH. The I CaL was elicited using a 200 ms voltage step from À40 to +10 mV from a holding potential of À80 mV prior to a 100 ms prepulse to À40 mV to inactivate the I NaP .
Randomization and blinding
Since our experiments were conducted in isolated cells and tissue preparations, animals were not randomized, as each tissue preparation or single cell served as its own control. Animal experiments and data analyses were also not performed under blind conditions. The procedure for data analysis is standardized and always done with automatic routines built in the analysis programme. This standardized approach reduces any possible operator bias and the need of blinding.
Data analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Percentage values and normalization for changes in ionic currents were used in the present manuscript in order to control for the large variation among different cells and in order to fit the recorded data with related equations. The Statistical Package for Social Sciences (SPSS, version 13.0, IBM, USA), pCLAMP 10.1 software (Molecular Devices, LLC, USA), Spike 2 (Version 7, Cambridge Electronic Design Limited, UK), Origin 8 software (Microcal Software, USA) and GraphPad Prism 5 (GraphPad Software, La Jolla, USA) were used for data acquisition and analysis. All data are expressed as mean ± SEM. Voltagedependent activation and inactivation curves of the sodium channel were fitted to Boltzmann relations, and the steadystate recovery curve was fitted to a biexponential equation. To calculate the IC 50 of the drug, dose-response data were fitted with the Hill equation. Intragroup statistical comparisons were performed with Student's paired t-test, while intergroup comparisons were performed with Student's unpaired t-test. Fisher's exact test was used to analyse the difference in incidence rate of arrhythmia events. A P value less than 0.05 was deemed to be statistically significant. For the single cardiomyocyte study, both cell number and animal number were shown, and cells were isolated from at least five rabbits in each experiment.
Materials
All solutions were prepared with Milli-Q grade water. The standard Tyrode solution contained (in mM): 5.4 KCl, 135 NaCl, 1.0 MgCl 2 , 0.33 NaH 2 PO 4 , 10 glucose, 10 HEPES and 1.8 CaCl 2 , and pH was adjusted to 7.4 with NaOH. The Ca 2+ -free Tyrode solution was devoid of Ca 2+ . The enzymes used to dissociate cells were dissolved in Ca 2+ -free Tyrode solution to achieve the referred concentrations. The KB solution contained (in mM): 50 K-glutamate, 85 KOH, 30 KCl, 10 HEPES, 20 taurine, 10 glucose, 1.0 MgCl 2 , 0.5 EGTA, pH 7.4 (KOH). 9-Phenanthrol and flufenamic acid (FA) were dissolved in DMSO to make stock solutions of 0.1 M. The stock solutions of I NaL inhibitor GS967 (MedChem Express, China), ATX-II (Alomone Labs, USA), nifedipine and TTX (Alomone Labs) were dissolved according to the manufacturer's instructions. All chemicals were bought from SigmaAldrich (USA) unless otherwise stated.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017).
Results

9-Phenanthrol shortened APD and eliminated ATX-II-induced APD prolongation and EADs in isolated VMs
We first investigated the effect of 9-phenanthrol by recording APs in VMs, and our results showed that 9-phenanthrol (30 μM) shortened APD 90 from 198.5 ± 11.2 to 177 ± 10 ms (P < 0.05, n = 7, Figure 1A ,B), and had no significant effects on APA, RMP or Vmax (Table 1) . When 2 nM ATX-II was added to prolong APD, the addition of 10 and 30 μM 9-phenanthrol shortened APD 90 in a dose-dependent manner ( Figure 1C,D) . APD 90 in VMs changed from 276 ± 18.7 to 209 ± 12.8 ms (P < 0.05, n = 6) and from 209 ± 12.8 to 170.4 ± 10.8 ms (P < 0.05, n = 6) respectively. At a higher concentration (10 nM), ATX-II induced a greater increase in APD and facilitated the occurrence of EADs, and 9-phenanthrol (10 μM) ameliorated these cellular arrhythmias and reversed it to normal at a concentration of 30 μM ( Figure 1E and Supporting Information Figure S1 ). The incidence of EADs caused by ATX-II was reduced from 100 to 0% (n = 6, P < 0.05) when 30 μM 9-phenanthrol was added ( Figure 1F ). To test whether the antiarrhythmic effect of 9-phenanthrol in our study was due to TRPM4 inhibition, we used FA, another commonly used inhibitor of TRPM4. And we observed that at a concentration (10 μM) that could specifically block TRPM4, FA could not reverse 10 nM ATX-IIinduced APD prolongation or EADs in VMs (n = 8; Supporting Information Figure S2 ).
9-Phenanthrol stabilized ventricular repolarization and eliminated ATX-II induced torsade de pointes (TdP) in arterially perfused rabbit wedge preparation
We also test the effect of 9-phenanthrol in arterially perfused rabbit left ventricular wedge preparations. As shown in Figure 2A , 9-phenanthrol (10 and 30 μM) shortened the QT interval and Tp-e interval in a dose-dependent manner, while a minimal effect on QRS duration was seen. The QT and Tp-e intervals were reduced by 17.3 ± 2.9% (n = 6, P < 0.05, Figure 2B ) and 22.8 ± 3.3% (n = 6, P < 0.05) in the presence of 30 μM 9-phenanthrol. In another group, 30 nM ATX-II was used to mimic the condition of LQT3 (Figure 2C) , and the addition of 30 μM 9-phenanthrol attenuated ATX-II-induced EADs and TdP, and 50 μM reversed it to normal in five of five preparations. Meanwhile, the effect of FA in arterially wedge preparations was also tested. FA (10 μM) showed little effect on QRS duration, QT or Tp-e interval (Supporting Information- Figure S3A ,B) and could not reverse ATX-II-induced arrhythmias (Supporting Information Figure S3C ).
9-Phenanthrol inhibited I NaL in VMs
As ATX-II was an enhancer of I NaL , we next examined the effect of 9-phenanthrol on I NaL . Figure 3A displayed the representative I NaL recorded in the presence of 10 nM ATX-II, and 9-phenanthrol (10 and 30 μM) inhibited I NaL in a dosedependent manner. The average magnitude of I NaL at À20 mV reduced from À1.25 ± 0.13 to À0.37 ± 0.09 pA/pF (P < 0.05, n = 6) when 30 μM 9-phenanthrol was added ( Figure 3B ). The IC 50 for I NaL was 18 μM ( Figure 3C ).
Effect of 9-phenanthrol on I NaP in VMs
The effect of 9-phenanthrol on I NaP was also explored. 9-Phenanthrol at 30 μM only slightly inhibited I NaP ( Figure 4A) . The averaged peak current at À25 mV reduced from À22.6 ± 0.9 to À19.1 ± 1 pA/pF (P < 0.05, n = 10) at 30 μM and to À8.6 ± 0.7 pA/pF (P < 0.05, n = 10) at 100 μM ( Figure 4B ). No significant effect on the voltage-dependent activation curve was seen ( Figure 4C ). However, 9-phenanthrol dose-dependently shifted the steady-state inactivation curve of I NaP to the negative position ( Figure 4D and Table 2 ). In addition, 30 μM 9-phenanthrol did not influence the steady-state recovery curve of I NaP ( Figure 4E ), while at higher concentration (100 μM), 9-phenanthrol slowed steady-state recovery of I NaP . Summary data were shown in Table 2 . The IC 50 for I NaP was 71.5 μM ( Figure 4F ).
Antiarrhythmic effect of 9-phenanthrol in cardiac PCs
We also examined the role of 9-phenanthrol in cardiac PCs. In consistent with results from VMs, 9-phenanthrol (30 μM) caused a great reduction of APD 90 in PCs which changed (Table 1) . However, 30 μM 9-phenanthrol caused no further reduction of APD 90 when PCs were pretreated with 1 μM GS967 ( Figure 5B,C) . In addition, 9-phenanthrol at 30 μM effectively inhibited ATX-II (2 nM) induced AP prolongation and EADs in 8/8 PCs ( Figure 5D ). Spontaneous firings of PCs that occurred in the presence of 5 nM ATX-II were also terminated by 9-phenanthrol ( Figure 5E ,F). Further study revealed that 9-phenanthrol inhibited endogenous I NaL of PCs with an IC 50 of 10.7 μM ( Figure 5G ,H). As for FA (10 μM), minimal effects on APD, I NaL or ATX-II-induced arrhythmias were seen (Supporting Information- Figure S4 ).
9-Phenanthrol inhibited I NaL in HEK293 cells transfected with LQT3 mutation
Na v 1.5 encoded by SCN5A was the major sodium channel subtype in the heart; however, the relatively small magnitude of I NaL in cells transfected with WT SCN5A (Supporting Information Figure S5 ) made it hard to quantify, and we thus explored the effect of 9-phenanthrol on two canonical LQT3 mutations in HEK293 cells. The WT, S1904L and ΔKPQ mutant plasmid of SCN5A were transfected into HEK 293 cells, and our results showed that both mutants displayed enlarged I NaL compared with WT ( Figure 6A ,B). 9-Phenanthrol significantly inhibited I NaL of both mutants at a concentration of 30 μM ( Figure 6C,D) . As shown in Figure 6E , I NaL of S1904L and ΔKPQ mutants reduced by 74.7 ± 4.1 and 71 ± 5.3% respectively (P < 0.05, n = 7 in both groups) in the presence of 30 μM 9-phenanthrol.
Effect of 9-phenanthrol on I CaL in VMs
I CaL played an important role in the genesis of EADs; therefore, the effect of 9-phenanthrol on I CaL was also studied. As shown in Figure 7 , 9-phenanthrol at 100 μM did not show a significant effect on I CaL , and the peak current at 10 mV changed from 13.0 ± 0.8 to 12.4 ± 0.8 pA/pF (n = 9).
Discussion
In this study, we demonstrated that 9-phenanthrol shortens APD, stabilizes ventricular repolarization and abolishes arrhythmias induced by ATX-II in isolated VMs and PCs as well as in arterially perfused left ventricular wedge preparations. Further study revealed that 9-phenanthrol selectively inhibits I NaL both in cardiomyocytes and HEK293 cells expressing SCN5A mutations with an IC 50 approximating to that of TRPM4. 9-Phenanthrol also inhibited I NaP in a dosedependent manner with an IC 50 being four times larger than that of I NaL . To our knowledge, this is the first study to address the detailed pharmacological effects of 9-phenanthrol on cardiac I NaL and I NaP . 
9-Phenanthrol inhibited cardiac I NaL and effectively terminated ATX-II-induced arrhythmias
Enhanced I NaL has been linked with excessive prolongation of APD, the occurrence of EADs and increased transmural dispersion of repolarization, especially under pathophysiological conditions, such as LQT3, heart failure, oxidative stress and ischaemia-reperfusion (Remme and Wilde, 2013; Belardinelli et al., 2015; Fei et al., 2017) . In our study, we used the known I NaL enhancer ATX-II to increase this persistent current which resulted in prolonged APD and occurrence of EADs and TdP. 9-Phenanthrol (30 and 50 μM) shortened APD 90 and effectively terminated ATX-II-induced arrhythmias both in isolated VMs (Figure 1 ) and wedge preparations (Figure 2 ). It was unlikely that these effects were merely due to TRPM4 inhibition, as FA, another commonly used inhibitor of TRPM4, at a concentration (10 μM) that could specifically block TRPM4 was insufficient to reverse ATX-II-induced APD prolongation or EADs (Supporting Information Figures S2-S4 ). By directly recording I NaL in VMs, we have also shown the dose-response relation of 9-phenanthrol on I NaL was consistent with its effective concentration on ATX-II induced arrhythmias (Figure 3 ). The I NaL inhibition effect of 9-phenanthrol was also proved in HEK293 cells expressing the S1904L and ΔKPQ mutants of SCN5A, two canonical mutants that have been previously demonstrated with enlarged I NaL (Bennett et al., 1995; Bankston et al., 2007) (Figure 6 ).
Figure 3
9-Phenanthrol inhibited I NaL in VMs. (A) 10 nM ATX-II was used to enlarge I NaL , and the addition of 10 and 30 μM 9-phenanthrol attenuated ATX-II-enlarged I NaL . I NaL was elicited by voltage pulses from À120 to À20 mV at 0.2 Hz. Inset shows superimposed I NaL recorded in control and in the presence of 10 nM ATX-II. (B) Current and voltage relationship of I NaL in the presence of 10 nM ATX-II and ATX-II plus 30 μM 9-phenanthrol, n = 6 cells from five rabbits. (C) The dose-response curve for effect of 9-phenanthrol on ATX-II-enlarged I NaL . n = 7 to 20 cells as indicated over data points; cells were obtained from eight rabbits, and the IC 50 was 18 μM.
Figure 4
Effect of 9-phenanthrol on I NaP in VMs. (A) Representative I NaP traces in control and in the presence of 30 μM 9-phenanthrol. Inset shows the voltage protocol. I NaP was elicited at a holding potential of À120 mV. (B) Summary data of current-voltage curves in control and in the presence of 30 and 100 μM 9-phenanthrol. The peak current at À25 mV was reduced from À22.6 ± 0.9 to À19.1 ± 1 pA/pF (P < 0.05) and À8.6 ± 0.7 pA/pF (P < 0.05), respectively, n = 10 cells from six rabbits. (C) Voltage-dependent activation curves of I NaP in control and in the presence of 30 and 100 μM 9-phenanthrol. n = 10 cells from six rabbits. (D) Steady-state inactivation curves of I NaP in control and in the presence of 30, 50 and 100 μM 9-phenanthrol. n = 7 cells from six rabbits, inset (left) showed the voltage protocol. (E) Recovery curves of I NaP in control and in the presence of 30 and 100 μM 9-phenanthrol, n = 9 cells from six rabbits. (F) The dose-response curve for effect of 9-phenanthrol on I NaP . The IC 50 was 71.5 μM, n = 11 cells at all concentrations; data were collected from six rabbits. Table 2 Effect of 9-phenanthrol on kinetic properties of I NaP
Voltage-dependence of activation (n = 10)
Voltage-dependence of inactivation (n = 7)
Recovery from inactivation (n = 9)
Control À38.2 ± 0.3 6.0 ± 0.3 À75.9 ± 0.5 À8.9 ± 0.5 6.7 ± 0.3 42.1 ± 2.2 30 μM À39.4 ± 0.3 6.5 ± 0.3 À82.7 ± 0.5* À10 ± 0.5 7.9 ± 0.2 44.5 ± 1.8 50 μM / / À86.7 ± 0.7 * À10.9 ± 0.6* / / 100 μM À39.4 ± 0.3 6.4 ± 0.3 À93.9 ± 0.5* À11.1 ± 0.4* 21.7 ± 0.5* 101.2 ± 9.1* V 1/2 , voltage for half activation or inactivation; k, slope factor; τf, the fast component of time constant; τs, the slow component of time constant; *P < 0.05 compared with control value, cells were isolated from six rabbits.
In addition, it was unlikely that the antiarrhythmic effects of 9-phenanthrol were due to I CaL inhibition, as 9-phenanthrol did not show a significant effect on I CaL at the highest concentration evaluated in our study (Figure 7 ).
Possible role of 9-phenanthrol in hypoxia and ATX-II-induced arrhythmias
Previously, 9-phenanthrol has been reported to abolish hypoxia and re-oxygenation-induced EADs in mouse right ventricle preparation at 10 and 100 μM (Simard et al., 2012), Figure 5 9-Phenanthrol abolished cellular arrhythmias in cardiac PCs. (A) Representative APs of PC recorded in control and in the presence of 30 μM 9-phenanthrol at a BCL of 2 s. (B) Representative APs of PC recorded in control and in the presence of 1 μM GS967 and GS967 plus 30 μM 9-phenanthrol at a BCL of 2 s. (C) Summary data of APD 90 in the above conditions, n = 7 cells and 6 cells, respectively, data were collected from five rabbits, *P < 0.05 versus control value. (D) 9-Phenanthrol (10 and 30 μM) eliminated 2 nM ATX-II-induced APD prolongation and EADs in a representative cell (left), and summary data are shown on the righthand side. BCL = 5 s, n = 8 cells from five rabbits, *P < 0.05 versus ATX-II value. (E) 5 nM ATX-II was used to induce spontaneous firing in PC, and 10 μM 9-phenanthrol reversed it to normal (top). a and b (bottom) indicate expanded area of that marked with red arrows above. (F) Incidence of spontaneous firing in control and in the presence of 5 nM ATX-II and ATX-II plus 10 and 30 μM 9-phenanthrol in PCs, n = 6 cells from five rabbits, *P < 0.05 versus ATX-II alone value. (G) Representative endogenous I NaL of PC recorded in control and in the presence of 9-phenanthrol (3, 10 and 30 μM). I NaL was elicited by voltage pulses from À120 to À20 mV at 0.2 Hz. (H) The dose-response curve for effect of 9-phenanthrol on endogenous I NaL in PCs, n = 6 to 21 cells as indicated over data points; data were collected from eight rabbits, and the IC 50 was 10.7 μM.
9-Phenanthrol inhibits cardiac sodium channel
and 10 μM 9-phenanthrol has also been demonstrated to terminate angiotensin II-induced EADs in HL-1 cells (Hu et al., 2017) . While in our study, 10 and 100 μM 9-phenanthrol inhibited ATX-II-enlarged I NaL by 31.6 ± 3.2% (n = 19) and 95.7 ± 1.3% (n = 20) in rabbit VMs. I NaL also played an important role in ischaemia-reperfusion or angiotensin II-induced arrhythmias, and I NaL inhibition could markedly reduce related arrhythmias (Le Grand et al., 2008; Dhalla et al., 2009; Zhao et al., 2011) . Therefore, the antiarrhythmic effects of 9-phenanthrol in hypoxia and re-oxygenation-or angiotensin II-induced EADs model may be partially due to direct inhibition of I NaL . In contrast to results from a previous study conducted in the hypoxic model, minimal effects of 10 μM FA were seen in the ATX-II-induced arrhythmia model; we thus speculated that TRPM4 was mainly involved in hypoxiainduced arrhythmias and I NaL in ATX-II-induced arrhythmias. Since 9-phenanthrol modulates both channels while FA (10 μM) only inhibits the TRPM4 channel, 9-phenanthrol would have an effect in both models.
9-Phenanthrol inhibited I NaP
Meanwhile, 9-phenanthrol caused a dose-dependent inhibition of I NaP , and our results indicated that 9-phenanthrol mainly affected the inactivation state of the sodium channel 
Figure 7
Effect of 9-phenanthrol on I CaL in VMs. (A) Representative I CaL recorded in control and in the presence of 30 μM 9-phenanthrol. I CaL was recorded using a 200 ms step from À40 to +10 mV at a holding potential of À80 mV prior to a 100 ms prepulse to À40 mV. (B) Summary data of I CaL at different conditions, n = 9 cells from five rabbits, P > 0.05 versus control value. (Figure 4) . At a therapeutic concentration (30 μM), its effect on I NaP was relatively small in VMs. Previous studies using mouse atrial preparations concluded that 9-phenanthrol (10-100 μM) did not influence APA or Vmax Simard et al., 2013) of APs, while in our study, 100 μM 9-phenanthrol inhibited I NaP by 63 ± 3.7% (n = 11) in rabbit VMs. This discrepancy could be due to difference in species, cell types and methodology. Unlike previous studies which were conducted in tissue preparations, isolated cells were used in our experiment, and pharmacological effects of 9-phenanthrol were amplified in single isolated cells because of cellular uncoupling and hydrophobicity of 9-phenanthrol. In addition, I NaP was recorded in low Na + (10 mM) bath solution for better voltage control, while Vmax was measured in bath solution with physiological concentration (140 mM) of Na + . Moreover, the different temperatures used to record Vmax (37°C) and I NaP (room temperature) may also account for this discrepancy. 9-Phenanthrol (10-100 μM) has also been reported to mitigate calcium oscillation in HL-1 mouse cardiomyocytes (Burt et al., 2013) and terminate burst firing in a neuronal system (Mrejeru et al., 2011) , and again these may partially attributed to sodium current inhibition.
Electrophysiological effect of 9-phenanthrol in cardiac PCs
Cardiac Purkinje fibres play an important role in maintaining rapid impulse propagation from atrioventricular node to ventricle and in the genesis of various arrhythmias, such as catecholaminergic polymorphic ventricular tachycardia (Willis et al., 2016) , idiopathic ventricular tachycardia (Xiao et al., 2013) . Our previous studies indicated that I NaL in PCs displayed larger rate-dependent property, slower decay and recovery kinetics compared with VMs , and I NaL inhibition ameliorated rate-dependent adaption of APD and effectively terminated related arrhythmias in PCs (Hou et al., 2016; Li et al., 2017) . Therefore, we tested the effect of 9-phenanthrol on PC-related arrhythmias. Consistent with results from VMs, 9-phenanthrol inhibited endogenous I NaL of PCs with an IC 50 of 10.7 μM, so there was no surprise that 30 μM 9-phenanthrol effectively abolished ATX-II-induced arrhythmias in PCs ( Figure 5) .
Recent evidence suggested a relatively abundant expression of TRPM4 channels in PCs (Kruse et al., 2009 ) and TRPM4-like single channel activity has also been observed in rabbit PCs (Hof et al., 2016) . However, its role in PCs remains to be clarified. A study conducted by Guinamard's lab (Hof et al., 2016) concluded that the TRPM4 current modulated AP morphology in PCs. In their study, the APD 90 of Purkinje fibres was reduced by about 15% in the presence of 30 μM 9-phenanthrol. Nevertheless, I NaL also played a crucial role in modulating the APD of PCs, which has been demonstrated in various studies (Sicouri et al., 2013; Hou et al., 2016; Li et al., 2017) as well as in mathematical models (Corrias et al., 2011) . In accordance with the results from Guinamard's lab, we observed that 30 μM 9-phenanthrol significantly shortened the APD 90 of PCs ( Figure 5A,C) ; however, this effect was diminished when PCs were pretreated with 1 μM GS967 (a selective inhibitor of I NaL ) ( Figure 5B,C) . In addition, the I NaL of PCs was reduced by 82.4 ± 2.6% in the presence of 30 μM 9-phenanthrol in our experiments ( Figure 5G,H) . Thus, to precisely reveal the role of TRPM4 in PCs, perhaps a more specific blocker of TRPM4 or a knockout animal model is needed.
Clinical and therapeutic implications
Our study indicates that 9-phenanthrol selectively inhibits cardiac I NaL and terminates related arrhythmias in an LQT3 model. Considering the benefits of I NaL inhibition in various pathophysiological models, 9-phenanthrol may thus serve as a potential candidate for discovering antiarrhythmic drugs. However, previous studies (Rich and Horsfall, 1954; Bucker et al., 1979; Hill et al., 1983) have indicated the fungitoxicity, cytotoxicity and mutagenicity of 9-phenanthrol, which may limit its use in vivo.
Collectively, our results provide an important and novel explanation for the antiarrhythmic and cardioprotective effects of 9-phenanthrol.
Limitations of study
Several study limitations should be mentioned. First, we cannot exclude a role of TRPM4 inhibition in the termination of ATX-II-induced EADs and AP prolongation, as excessive sodium influx caused by ATX-II may activate the reverse mode of the sodium-calcium exchanger (NCX), which in turn increases intracellular calcium and thus activates the TRPM4 channel. Therefore, a combined inhibition of TRPM4 and I NaL may contribute to 9-phenanthrol's antiarrhythmic property. Furthermore, a recent study indicated that 9-phenanthrol can also inhibit the Ca 2+ -activated Cl À current conducted by the TMEM16A channel (Burris et al., 2015) . However, this current contributes to phase 1 repolarization, inhibition of which may prolong APD and facilitate the occurrence of EADs (Hegyi et al., 2017) . As a result, it is unlikely that the antiarrhythmic effect of 9-phenanthrol is due to TMEM16A channel inhibition. Moreover, in another study it was reported that 9-phenanthrol can activate the intermediate conductance Ca 2+ -activated potassium channel (K Ca 3.1) (Garland et al., 2015) . However, the role of K Ca 3.1 in cardiac electrophysiology has not been fully explored, and the RMP either in VMs or in PCs was not influenced by 9-phenanthrol in our study.
Conclusion
Our results suggest that 9-phenanthrol, a widely used inhibitor of TRPM4, can modulate the gating property of the cardiac sodium channel and inhibit cardiac I NaP and I NaL , which may contribute to its observed antiarrhythmic and cardiac protective effects. Considering the multi-channel inhibition property of 9-phenanthrol, one should be cautious when trying to interpret any results obtained with 9-phenanthrol.
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https://doi.org/10.1111/bph.14490( Figure S1 Representative APs of VM in the presence of ATX-II and ATX-II plus 9-phenanthrol and after washing out 9-phenanthrol. Allows indicated occurrence of EADs. ATX-II induced cellular arrhythmia can't be reversed by 10 μM FA in 7 of 7 cells, cells were disassociated from five rabbits. However, the significant reduction of action potential amplitude at 30 μM also indicated that FA (30 μM) could modulate sodium current. Figure S5 Effect of 9-phenanthrol (9-phe) on sodium current recorded in HEK 293 cells transfected with WT SCN5A. (A) Representative I NaL recorded in control and presence of TTX, notice that the physiological I NaL was relatively small. (B) Representative I NaP recorded in control and presence of 9-phenanthrol. A magnification of I NaL in the same cell was also shown. Despite the small magnitude of I NaL , the acceleration of decay also indicated the inhibitory effect of 9-phenanthrol on I NaL of non-mutated Nav1.5 channel.
